Therapy-related myeloid neoplasms

Area of Science:

• Hematology
• Oncology
• Genetics

Background:

• Therapy-related myeloid neoplasms (t-MN) represent an increasing challenge in cancer survivorship.
• The 2008 WHO classification and advancements in genome-wide association studies have refined understanding of t-MN.
• Aggressive cancer treatments necessitate a re-evaluation of t-MN risks.

Purpose of the Study:

• To provide an updated review of therapy-related myeloid neoplasms (t-MN).
• To incorporate the latest 2008 WHO classification for t-MN.
• To discuss new genome-wide approaches for identifying susceptibility to t-MN and the impact of novel cancer therapies.

Main Methods:

• Review of current literature on therapy-related myeloid neoplasms.
• Analysis of data regarding the 2008 WHO classification of myeloid neoplasms.
• Examination of genome-wide studies on t-MN susceptibility.
• Assessment of risks associated with new cancer treatment modalities.

Main Results:

• t-MN incidence is notable in survivors of childhood acute lymphoblastic leukemia, Hodgkin lymphoma, and breast cancer.
• Specific chemotherapy regimens (e.g., BEACOPP vs. ABVD) and drugs (etoposide, fludarabine, lenalidomide) are associated with increased t-MN risk.
• Radiotherapy, G-CSF use, and genetic predisposition may contribute to t-MN development, particularly in breast, pelvic, and testicular cancers.

Conclusions:

• The risk of t-MN, while generally under 2%, is significant, especially for young cancer patients within five years of primary treatment.
• Identifying individuals susceptible to t-MN is paramount.
• Avoiding highly leukemogenic drugs and treatment schedules in at-risk patients is essential for mitigating t-MN development.